Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Savolitinib + Osimertinib vs Savolitinib + Placebo in EGFRm+ MET Amplified NSCLC
NCT04606771Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of savolitinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Sep 2020; status: active, not recruiting.
02
Drugs
savolitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04606771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04606771.